Press Releases


September 26, 2015 Aduro Biotech Announces Phase 1b Mesothelioma Trial Featured in Spotlight Poster at ESMO/ECC

September 25, 2015 Met de overname van BioNovion versterkt Aduro Biotech haar belangrijke antilichaam-portfolio en -onderzoekcapaciteit.

September 24, 2015 Aduro Biotech Enters Into Definitive Agreement to Acquire Premier Antibody Portfolio and Engineering Capabilities Through Purchase of BioNovion

September 23, 2015 Aduro Biotech to Participate in Leerink Partners Immuno-Oncology Roundtable

September 21, 2015 Aduro Biotech Appoints Blaine Templeman as Executive Vice President, General Counsel and Secretary

September 09, 2015 Aduro Biotech Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies for the Treatment of Ovarian Cancer

September 08, 2015 Aduro Biotech Completes Enrollment in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer

September 02, 2015 Aduro Biotech to Present at BioCentury's NewsMakers in the Biotech Industry Conference

August 10, 2015 Aduro Biotech Announces Second Quarter 2015 Financial Results

August 10, 2015 Aduro Biotech Completes Enrollment in Phase 1b Clinical Trial of CRS-207 Immunotherapy for the Treatment of Mesothelioma

August 06, 2015 Aduro Biotech to Present at the 35th Annual Canaccord Genuity Growth Conference

June 29, 2015 Aduro Biotech Announces Immunotherapy Regimen Successfully Passes Futility Analysis in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer

June 26, 2015 Aduro Biotech Appoints Industry Veteran, Stephen Sherwin, M.D., to Its Board of Directors

June 02, 2015 Aduro Biotech Appoints Liana Wu as Vice President of Commercial

June 01, 2015 Aduro Biotech Announces ASCO Presentation of Encouraging Data From Ongoing Phase 1b Clinical Trial of Its Immunotherapy for the Treatment of Mesothelioma

May 28, 2015 Aduro Biotech Announces First Quarter 2015 Financial Results

May 07, 2015 Aduro Biotech's Preclinical Results for Its STING-Targeted CDN Immuno-Oncology Platform Highlighted in Prestigious Peer-Reviewed Publications

May 06, 2015 Aduro Biotech to Present at Bank of America Merrill Lynch 2015 Health Care Conference

April 20, 2015 Aduro Biotech Announces Close of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Concurrent Private Placement

April 14, 2015 Aduro Biotech Announces Pricing of Its Initial Public Offering

March 30, 2015 Aduro Biotech Establishes Major Collaboration with Novartis for Global Research, Development and Commercialization of Immuno-Oncology Products Derived from its Proprietary STING-Targeted CDN Platform Technology

March 26, 2015 Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma

February 26, 2015 Aduro Biotech Collaborates with Leaders in Cancer Research on Investigator-Sponsored Phase 2 Trial Combining Aduro’s Innovative Immunotherapies with Anti-PD-1 Technology to Treat Patients with Advanced Pancreatic Cancer

February 11, 2015 Aduro appoints Sylvia R. Wheeler as senior vice president, corporate affairs and investor relations

February 09, 2015 Aduro meets development milestone in immuno-oncology collaboration with Janssen for treatment of prostate cancer

January 20, 2015 Aduro Biotech reports long-term survival and immune biomarker data from Phase 2 clinical trial of its immuno-oncology regimen in patients with pancreatic cancer

January 12, 2015 Aduro Biotech announces Phase 2 clinical trial results for pancreatic cancer combination immunotherapy published in Journal of Clinical Oncology

January 05, 2015 Aduro Biotech closes $51.4 million Series D financing